| Balance Sheets | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Cash | 1,948,271 | 206,233 | 1,346,543 | |
| Prepaid expenses and other | 419,421 | 783,189 | 618,971 | |
| Inventory | 35,437 | - | - | |
| Total current assets | 2,403,129 | 989,422 | 1,965,514 | |
| Total assets | 2,403,129 | 989,422 | 1,965,514 | |
| Accounts payable | 1,060,889 | 1,351,639 | 1,432,025 | |
| Accrued expenses | 266,930 | 378,181 | 319,067 | |
| Other current liabilities-Affiliates | 353,679 | 353,679 | 353,679 | |
| Other current liabilities | - | 0 | - | |
| Notes payable related party-Related Party | 885,564 | 1,331,357 | 1,211,346 | |
| Promissory note fee related party-Related Party | 1,000,000 | 1,000,000 | 1,000,000 | |
| Derivative liability | 3,554,265 | - | - | |
| Loan and transfer notes payable related party-Related Party | 499,214 | - | - | |
| Loan and transfer notes payable | - | 499,214 | 499,214 | |
| Subscription agreement loan | 1,500,000 | 2,025,344 | 1,878,268 | |
| Convertible note | 4,739,965 | 3,617,508 | 3,175,354 | |
| Total current liabilities | 13,860,506 | 10,556,922 | 9,868,953 | |
| Forward purchase agreement liability | 9,901 | 49,285 | 49,303 | |
| Total liabilities | 13,870,407 | 10,606,207 | 9,918,256 | |
| Common stock 0.0001 par value 490,000,000 shares authorized 49,525,970 and 27,601,767 issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 4,953 | 4,953 | 4,890 | |
| Additional paid-in capital | 11,078,116 | 11,078,116 | 10,760,929 | |
| Accumulated deficit | -22,550,347 | -20,699,854 | -18,718,561 | |
| Total shareholders deficit | -11,467,278 | -9,616,785 | -7,952,742 | |
| Total liabilities and shareholders deficit | 2,403,129 | 989,422 | 1,965,514 | |
Aspire Biopharma Holdings, Inc. (ASBPW)
Aspire Biopharma Holdings, Inc. (ASBPW)